Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Tumor-Tropic Adipose-Derived Mesenchymal Stromal Cell Mediated Bi 2 Se 3 Nano-Radiosensitizers Delivery for Targeted Radiotherapy of Non-Small Cell Lung Cancer.

Xiao J., Zeng L., Ding S., Chen Y., Zhang X., Bian XW.

Animal Study on Face & Skin, Systemic / IV, published in Adv Healthc Mater (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Healthc Mater (2022)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
35195958
DOI
10.1002/adhm.202200143
Citations
37

Abstract (original English)

With the successful marriage between nanotechnology and oncology, various high-Z element containing nanoparticles (NPs) are approved as radiosensitizers to overcome radiation resistance for enhanced radiotherapy (RT). Unfortunately, NPs themselves lack specificity to tumors. Due to the inherent tropism nature of malignant cells, mesenchymal stem cells (MSCs) emerge as cell-mediated delivery vehicles for functional NPs to improve their therapeutic index. Herein, radiosensitive bismuth selenide (Bi 2 Se 3 ) NPs-laden adipose-derived mesenchymal stromal cells (AD-MSCs/Bi 2 Se 3 ) are engineered for targeted RT of non-small cell lung cancer (NSCLC). The results reveal that the optimized intracellular loading strategy hardly affects cell viability, specific surface markers, or migration capability of AD-MSCs, and Bi 2 Se 3 NPs can be efficiently transported from AD-MSCs to tumor cells. In vivo biodistribution test shows that the Bi 2 Se 3 NPs accumulation in tumor is increased 20 times via AD-MSCs-mediated delivery. Therefore, AD-MSCs/Bi 2 Se 3 administration synchronized with X-ray irradiation controls the tumor progress well in orthotopic A549 tumor bearing mice. Considering that MSCs migrate better to irradiated tumor cells in comparison to nonirradiated ones and MSCs preferentially accumulate within lung tissues after systemic administration into accounts, the tumor-tropic MSCs/

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorLung NeoplasmsMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMiceRadiation-Sensitizing AgentsTissue Distribution

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research